Tixel i® Proves Effective for Patients with Dry Eye Disease in Recent Study
Tixel i® Proves Effective for Patients with Dry Eye Disease in Recent Study
A recent publication in JOJ Ophthalmology has highlighted the effectiveness of Tixel i®, a groundbreaking device by Novoxel, in treating Evaporative Dry Eye Disease (DED). The device, which is FDA-cleared, showcases impressive clinical outcomes for patients suffering from Meibomian Gland Dysfunction (MGD)—a leading cause of dry eyes.
What is Tixel i®?
Tixel i® utilizes a unique approach known as Thermo-Mechanical Action® (TMA®) to effectively treat dry eye symptoms in a non-invasive manner. The treatment is swift, generally taking less than two minutes, providing immediate relief without the need for extensive downtime. Doctors like Dr. Lauren Bailey from West Plano Dry Eye and Aesthetics have attested to the device’s transformative benefits on patients who previously encountered barriers in relief.
Significant Clinical Outcomes
In particular, the study presented compelling data demonstrating how Tixel i® improved several key indicators:
- - Tear Break-Up Time (TBUT): This parameter rose from an average of 4.0 ± 1.5 seconds to 9.2 ± 4.0 seconds, indicating a return to a more normal physiological state for the eyes.
- - Meibomian Gland Score (MGS): There was a remarkable increase of over 17 points, suggesting comparable efficacy to existing thermal pulsation systems.
- - Ocular Surface Disease Index (OSDI): Scores dropped by over 21 points, representing a marked decrease in dry eye symptoms and a substantially enhanced quality of life for patients.
- - Importantly, the study reported no device-related adverse effects, emphasizing the safety of the Tixel i® treatment.
Real-World Impact
Dr. Bailey highlighted the success stories of her patients, indicating that even those with severe dry eye symptoms who were intolerant to conventional treatments found significant relief with Tixel i®. For instance, one 76-year-old patient, previously reliant on traditional methods like intense pulsed light (IPL), experienced immediate and lasting comfort following Tixel i® therapy. Furthermore, a 53-year-old patient who used eye drops multiple times daily reported a significant reduction in discomfort following just three sessions. At her four-week follow-up, her symptoms had notably improved.
The results illustrate the optimistic potential of Tixel i® in addressing not just dry eyes but also improving the overall satisfaction of patients. This can be especially beneficial for those with low vision, who often struggle with dry eye management due to limited treatment options.
About Novoxel
Founded in 2011, Novoxel Ltd. is at the forefront of clinical and scientific innovation. Holding a multitude of patents globally, the company’s Tixel range employs proprietary TMA® technology to provide visible clinical outcomes. The treatments derived from Tixel are celebrated for being non-invasive, cost-effective, and free from the complications typically seen in other treatment modalities.
For individuals seeking a viable solution to manage their dry eye symptoms, Tixel i® demonstrates not only efficacy but a pathway to improve their quality of life markedly. Learn more about Tixel i® and how it can help you by visiting Novoxel's official website.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.